sq-11725 has been researched along with Disease Exacerbation in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, Y; Inagaki, T; Kuwahira, I; Nagai, H; Nara, A; Ogura, S; Pearson, JT; Schwenke, DO; Shimosawa, T; Shirai, M; Tsuchimochi, H; Uemura, K; Umetani, K; Yoshida, K | 1 |
| Avraham, R; Bartal, I; Ben-Eliyahu, S; Benish, M; Inbar, S; Rosenne, E | 1 |
| Gawrieh, S; Saeian, K | 1 |
| Bosch, J | 1 |
| Andreone, P; Berzigotti, A; Magalotti, D; Morelli, MC; Rinaldi, MF; Rossi, C; Zappoli, P; Zoli, M | 1 |
1 trial(s) available for sq-11725 and Disease Exacerbation
| Article | Year |
|---|---|
Is treatment with nadolol effective against the growth of small esophageal varices in patients with cirrhosis?
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Biopsy; Disease Progression; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Follow-Up Studies; Humans; Hypertension, Portal; Liver Cirrhosis; Middle Aged; Nadolol; Single-Blind Method; Treatment Outcome | 2005 |
4 other study(ies) available for sq-11725 and Disease Exacerbation
| Article | Year |
|---|---|
β2-Adrenergic receptor-dependent attenuation of hypoxic pulmonary vasoconstriction prevents progression of pulmonary arterial hypertension in intermittent hypoxic rats.
Topics: Adrenergic beta-2 Receptor Antagonists; Animals; Blood Pressure; Class Ia Phosphatidylinositol 3-Kinase; Disease Models, Animal; Disease Progression; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Male; Nadolol; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Pulmonary Artery; Rats; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Time Factors; Vasoconstriction | 2014 |
Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression.
Topics: Adjuvants, Immunologic; Adrenergic beta-Antagonists; Animals; Catecholamines; Cell Line, Tumor; Cyclooxygenase Inhibitors; Disease Progression; Flow Cytometry; Hormone Antagonists; Immune Tolerance; Indomethacin; Interleukin-12; Killer Cells, Natural; Laparotomy; Lung Neoplasms; Nadolol; Neoplasms, Experimental; Poly I-C; Postoperative Complications; Prostaglandin Antagonists; Rats; Rats, Inbred F344; Survival | 2010 |
Management of esophageal varices: an update from Digestive Disease Week and American Association for the Study of Liver Diseases 2003.
Topics: Adrenergic beta-Antagonists; Disease Progression; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Ligation; Nadolol; Recurrence | 2004 |
Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders.
Topics: Adrenergic beta-Antagonists; Blood Flow Velocity; Disease Progression; Female; Follow-Up Studies; Hepatic Veins; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Mesenteric Arteries; Middle Aged; Nadolol; Primary Prevention; Prospective Studies; Splanchnic Circulation; Treatment Outcome; Ultrasonography, Doppler, Duplex; Vasoconstriction | 2006 |